USA flag logo/image

An Official Website of the United States Government

IMMUNOTOXIN TREATMENT OF BLEPHAROSPASM AND STRAABISMUS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
19277
Program Year/Program:
1992 / SBIR
Agency Tracking Number:
19277
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Houston Biotechnology, Inc.
3608 Research Forest Drive. The Woodlands, TX 77381
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1992
Title: IMMUNOTOXIN TREATMENT OF BLEPHAROSPASM AND STRAABISMUS
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

BLEPHAROSPASM AND STRABISMUS ARE CHRONIC, DEBILITATING, OCULAR SPASTIC DISORDERS CAUSED BY UNCONTROLLED OR BALANCED MUSCLE CONTRACTION. THE LONG-TERM OBJECTIVE OF THIS WORK IS TO CREATE A THERAPEUTIC AGENT THAT WILL ABLATE CHOLINERGIC NEURONS RESPONSIBLE FOR THE MUSCLE CONTRACTION IN BLEPHAROSPASM AND STRABISMUS, AND TO TREAT HUMANS WITH THESE CONDITIONS. THE SPECIFIC AIMS INPHASE I ARE TO PRODUCE A HYBRIDOMA THAT SECRETES MONOCLONAL ANTIBODIES AGAINST A SPECIFIC CHOLINERGIC, NERVE TERMINAL MOLECULE, AND TO THEN CREATE AN IMMUNOTOXIN BY CONJUGATING THE MONOCLONAL ANTIBODY TO RICIN A TOXIN. WHEN ADMINISTERED, THE IMMUNOTOXIN WILL BECOME INTERNALIZED IN THE CHOLINERGIC NERVE TERMINAL AND KILL THE CHOLINERGIC NERVE. THIS APPROACH HAS AN ADVANTAGE OVER PRESENT TREATMENTS IN THAT FEWER TREATMENTS WILL BE NEEDED AND THERE MAY BE A PERMANENT CURE. THERE ARE A NUMBER OF OTHER RELATED, NON-OCULAR SPASTIC DISORDERS FOR WHICH THIS IMMUNOTOXIN COULD ALSO BE USED. THIS IS THE FIRST TIME AN IMMUNOTOXIN HAS BEEN DEVISED TO TREAT THESE DISORDERS.

Principal Investigator:

Thomas L Wallace
7133630999

Business Contact:

Small Business Information at Submission:

Houston Biotechnology
3608 Research Forest Drive The Woodlands, TX 77381

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No